In the press
New York biotech firm moving HQ to Cincinnati
New York biotech firm moving HQ to Cincinnati
The following excerpt was taken from Cincyinno Business Journal — continue reading here.
A New York-based biotech firm is moving its corporate headquarters to the University of Cincinnati’s 1819 Innovation Hub
“A New York-based biotech firm is moving its corporate headquarters to the University of Cincinnati’s 1819 Innovation Hub — the first out-of-state company to officially plant roots in the budding Cincinnati Innovation District. Orange Grove Bio, a preclinical drug investment and development firm, selected space on the third floor of 1819. Its lease in Avondale went into effect Monday.”
Related Press
How to Invest in Biotech Series – Phases, Stages, and Pitfalls
Emily Whitehead was 5 years old when she was diagnosed with acute lymphoblastic leukemia… Her cancer was resistant to traditional treatments and her prognosis was poor. In a final effort to save their daughter, her parents enrolled her in a clinical trial study at Children’s Hospital of Philadelphia for a new type of therapy called… Continue reading How to Invest in Biotech Series – Phases, Stages, and Pitfalls
Upcoming Webinar for Pre-Clinical Biotech Development Opportunities on April 16th at 1 PM EST.
Upcoming Webinar for Pre-Clinical Biotech Development Opportunities on April 16th at 1 PM EST. Please join us to hear from our CEO, Marc Appel.– continue reading here. Upcoming Webinar for Pre-Clinical Biotech Development Opportunities
Orange Grove Bio and Cincinnati Children’s Hospital Medical Center Establish Collaboration
Orange Grove Bio, a preclinical drug investment and development firm, and Cincinnati
Leading Korean VC partners with USA’s Orange Grove
Orange Grove Bio, a USA-based pre-clinical drug investment and development firm, and SV Investment, a South Korea-based venture capital and private equity firm, today announced the establishment of a new partnership through which the companies will collaborate on jointly sourcing and developing novel therapeutics in the USA and Korea. As priority partners, the companies will cultivate the US and Korean biotech landscape through technology licensing and company creation in their respective geographic areas.
Under terms of the partnership, SV Investment will leverage its relationships with biotech companies and academic institutions in Korea to identify licensing opportunities for promising early-stage research in the area of drug development. As part of the agreement, Marc Appel, chief executive of Orange Grove, will join SV Investment as a venture partner and will play a key role in evaluating the licensing opportunities that are identified at Korean biotech companies and universities. As appropriate, Orange Grove will work to license these technologies as a basis for life science company creation in the USA, with SV Investment serving as an early-stage investor in the companies.
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio The following was taken from PR Newswire and you can read it here: https://www.prnewswire.com/news-releases/research-bridge-partners-seed-capital-investment-in-asalyxa-bio-advances-dr-lola-eniola-adefesos-immune-cell-targeted-therapeutic-platform-301242853.html “Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities AUSTIN, Texas, March 9, 2021 /PRNewswire/ — Research Bridge Partners – a 501 (c) (3)… Continue reading Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry We are excited to announce our portfolio company, Ipinovyxbio‘s, launch! The following was taken from Fierce Biotech–read it here or continue below! “With a focus on autoimmune and inflammatory diseases, IpiNovyx Bio closed a $10 million seed financing round” “Eli Lilly is among the… Continue reading Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry
IF HENRY FORD WERE IN BIOTECH
IF HENRY FORD WERE IN BIOTECH Please join us to hear from our CEO, Marc Appel.
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition The following excerpt was taken from Einsteinmed.edu — continue reading here. Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend Albert Einstein College… June 27, 2022—(BRONX, NY)—Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend… Continue reading Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition
Orange Grove Bio: Filling the Gap in Preclinical Drug Development
Orange Grove Bio is a preclinical drug development company focused on driving down the cost of drug development… Orange Grove Bio, a preclinical drug investment and development firm, and the University of Pittsburgh today announced the establishment of a collaboration Orange Grove Bio is a preclinical drug development company focused on driving down the cost… Continue reading Orange Grove Bio: Filling the Gap in Preclinical Drug Development